NASDAQ:ARVN Arvinas (ARVN) Stock Forecast, Price & News $24.50 +0.25 (+1.03%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$23.95▼$25.7650-Day Range$21.73▼$28.5452-Week Range$21.21▼$58.58Volume416,192 shsAverage Volume364,728 shsMarket Capitalization$1.31 billionP/E RatioN/ADividend YieldN/APrice Target$67.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Arvinas MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside174.8% Upside$67.33 Price TargetShort InterestHealthy7.99% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.27Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($6.70) to ($7.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.91 out of 5 starsMedical Sector618th out of 987 stocksPharmaceutical Preparations Industry294th out of 481 stocks 3.4 Analyst's Opinion Consensus RatingArvinas has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 12 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $67.33, Arvinas has a forecasted upside of 174.8% from its current price of $24.50.Amount of Analyst CoverageArvinas has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.99% of the float of Arvinas has been sold short.Short Interest Ratio / Days to CoverArvinas has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Arvinas has recently decreased by 10.92%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldArvinas does not currently pay a dividend.Dividend GrowthArvinas does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARVN. Previous Next 2.4 News and Social Media Coverage News SentimentArvinas has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Arvinas this week, compared to 3 articles on an average week.Search Interest4 people have searched for ARVN on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Arvinas to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arvinas insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.55% of the stock of Arvinas is held by insiders.Percentage Held by Institutions92.03% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arvinas are expected to decrease in the coming year, from ($6.70) to ($7.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arvinas is -4.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arvinas is -4.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArvinas has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arvinas (NASDAQ:ARVN) StockArvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.Read More Receive ARVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter. Email Address ARVN Stock News HeadlinesJune 10, 2023 | msn.comWedbush Reiterates Arvinas (ARVN) Neutral RecommendationJune 10, 2023 | americanbankingnews.comArvinas (NASDAQ:ARVN) Stock Price Up 4.1%June 10, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Software" to Revolutionize WarfareThis breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>June 9, 2023 | msn.comHC Wainwright & Co. Reiterates Arvinas (ARVN) Buy RecommendationJune 9, 2023 | markets.businessinsider.com6 Analysts Have This to Say About ArvinasJune 8, 2023 | markets.businessinsider.comBank of America Securities Keeps Their Buy Rating on Arvinas Holding Company (ARVN)June 8, 2023 | markets.businessinsider.comGoldman Sachs Keeps Their Buy Rating on Arvinas Holding Company (ARVN)June 8, 2023 | finance.yahoo.comArvinas Releases Early Cut Data Showing Encouraging Efficacy In Prostate Cancer With Certain MutationsJune 10, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Software" to Revolutionize WarfareThis breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>June 8, 2023 | finance.yahoo.comArvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H MutationsJune 8, 2023 | americanbankingnews.comArvinas (NASDAQ:ARVN) versus Avenue Therapeutics (NASDAQ:ATXI) Head-To-Head ContrastJune 4, 2023 | americanbankingnews.comArvinas, Inc. (NASDAQ:ARVN) Receives $67.33 Consensus PT from AnalystsJune 1, 2023 | americanbankingnews.comArvinas (NASDAQ:ARVN) Sets New 52-Week Low at $21.86May 19, 2023 | msn.comLooking Into Arvinas's Return On Capital EmployedMay 17, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN)May 16, 2023 | americanbankingnews.comArvinas, Inc. (NASDAQ:ARVN) Sees Large Drop in Short InterestMay 14, 2023 | americanbankingnews.comAgile Therapeutics (NASDAQ:AGRX) vs. Arvinas (NASDAQ:ARVN) Critical SurveyMay 13, 2023 | msn.comMorgan Stanley Maintains Arvinas (ARVN) Equal-Weight RecommendationMay 13, 2023 | americanbankingnews.comFY2023 EPS Estimates for Arvinas, Inc. Raised by Analyst (NASDAQ:ARVN)May 12, 2023 | americanbankingnews.comArvinas, Inc. (NASDAQ:ARVN) Receives $67.87 Average PT from AnalystsMay 12, 2023 | americanbankingnews.comHC Wainwright Weighs in on Arvinas, Inc.'s FY2023 Earnings (NASDAQ:ARVN)May 10, 2023 | msn.comWhere Arvinas Stands With AnalystsMay 10, 2023 | markets.businessinsider.comOppenheimer Sticks to Their Buy Rating for Arvinas Holding Company (ARVN)May 10, 2023 | msn.comCredit Suisse Reiterates Arvinas (ARVN) Outperform RecommendationMay 10, 2023 | msn.comOppenheimer Reiterates Arvinas (ARVN) Outperform RecommendationMay 10, 2023 | americanbankingnews.comArvinas, Inc. Forecasted to Earn Q1 2024 Earnings of ($1.64) Per Share (NASDAQ:ARVN)May 9, 2023 | americanbankingnews.comStifel Nicolaus Lowers Arvinas (NASDAQ:ARVN) Price Target to $72.00See More Headlines ARVN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARVN Company Calendar Last Earnings5/05/2023Today6/10/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARVN CUSIPN/A CIK1655759 Webwww.arvinas.com Phone(203) 535-1456FaxN/AEmployees280Year FoundedN/APrice Target and Rating Average Stock Price Forecast$67.33 High Stock Price Forecast$95.00 Low Stock Price Forecast$27.00 Forecasted Upside/Downside+174.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($5.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-282,500,000.00 Net Margins-227.86% Pretax Margin-208.63% Return on Equity-50.85% Return on Assets-23.22% Debt Debt-to-Equity RatioN/A Current Ratio4.06 Quick Ratio4.06 Sales & Book Value Annual Sales$131.40 million Price / Sales9.96 Cash FlowN/A Price / Cash FlowN/A Book Value$10.61 per share Price / Book2.31Miscellaneous Outstanding Shares53,400,000Free Float52,036,000Market Cap$1.31 billion OptionableNot Optionable Beta1.75 Key ExecutivesJohn G. HoustonPresident, Chief Executive Officer & DirectorLisa SinclairSenior Vice President-Corporate OperationsSean A. CassidyChief Financial OfficerIan TaylorChief Scientific OfficerRonald PeckChief Medical OfficerKey CompetitorsLigand PharmaceuticalsNASDAQ:LGNDCatalyst PharmaceuticalsNASDAQ:CPRXSummit TherapeuticsNASDAQ:SMMTStructure TherapeuticsNASDAQ:GPCRCTI BioPharmaNASDAQ:CTICView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 1,243 shares on 5/26/2023Ownership: 0.018%Capital Impact Advisors LLCBought 5,280 shares on 5/23/2023Ownership: 0.025%Ameriprise Financial Inc.Bought 21,252 shares on 5/22/2023Ownership: 0.128%New York State Common Retirement FundSold 10,710 shares on 5/18/2023Ownership: 0.048%JPMorgan Chase & Co.Bought 3,200 shares on 5/18/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ARVN Stock - Frequently Asked Questions Should I buy or sell Arvinas stock right now? 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARVN shares. View ARVN analyst ratings or view top-rated stocks. What is Arvinas' stock price forecast for 2023? 16 brokers have issued 12-month price targets for Arvinas' stock. Their ARVN share price forecasts range from $27.00 to $95.00. On average, they anticipate the company's stock price to reach $67.33 in the next twelve months. This suggests a possible upside of 174.8% from the stock's current price. View analysts price targets for ARVN or view top-rated stocks among Wall Street analysts. How have ARVN shares performed in 2023? Arvinas' stock was trading at $34.21 at the beginning of 2023. Since then, ARVN stock has decreased by 28.4% and is now trading at $24.50. View the best growth stocks for 2023 here. When is Arvinas' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our ARVN earnings forecast. How were Arvinas' earnings last quarter? Arvinas, Inc. (NASDAQ:ARVN) announced its quarterly earnings data on Friday, May, 5th. The company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by $0.05. The business earned $32.50 million during the quarter, compared to analysts' expectations of $27.74 million. Arvinas had a negative trailing twelve-month return on equity of 50.85% and a negative net margin of 227.86%. Arvinas's revenue for the quarter was up 22.6% on a year-over-year basis. During the same quarter last year, the company earned ($1.20) EPS. What ETFs hold Arvinas' stock? ETFs with the largest weight of Arvinas (NASDAQ:ARVN) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), iShares U.S. Pharmaceuticals ETF (IHE), Harbor Disruptive Innovation ETF (INNO), Principal Healthcare Innovators ETF (BTEC) and BlackRock Future Health ETF (BMED). What other stocks do shareholders of Arvinas own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD). When did Arvinas IPO? (ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO. What is Arvinas' stock symbol? Arvinas trades on the NASDAQ under the ticker symbol "ARVN." Who are Arvinas' major shareholders? Arvinas' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (10.71%), BlackRock Inc. (8.38%), EcoR1 Capital LLC (6.96%), Price T Rowe Associates Inc. MD (4.71%), ArrowMark Colorado Holdings LLC (2.94%) and State Street Corp (2.07%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Timothy M Shannon. View institutional ownership trends. How do I buy shares of Arvinas? Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arvinas' stock price today? One share of ARVN stock can currently be purchased for approximately $24.50. How much money does Arvinas make? Arvinas (NASDAQ:ARVN) has a market capitalization of $1.31 billion and generates $131.40 million in revenue each year. The company earns $-282,500,000.00 in net income (profit) each year or ($5.66) on an earnings per share basis. How many employees does Arvinas have? The company employs 280 workers across the globe. How can I contact Arvinas? Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The official website for the company is www.arvinas.com. The company can be reached via phone at (203) 535-1456 or via email at ir@arvinas.com. This page (NASDAQ:ARVN) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.